earnings
confidence high
sentiment positive
materiality 0.80
Gilead Q3 revenue $7.0B, EPS $1.42; raises full-year guidance
GILEAD SCIENCES, INC.
2022-Q3 EPS reported
$2.34
revenue$19,892,000,000
- Total revenue $7.0B (-5% YoY); core product sales ex-Veklury up 11% to $6.1B.
- GAAP diluted EPS $1.42 (vs $2.05); Non-GAAP EPS $1.90 (vs $2.65).
- Biktarvy sales +22% to $2.8B; oncology sales +79% to $578M; Veklury -52% to $925M.
- Raises 2022 guidance: product sales $25.9-$26.2B, Non-GAAP EPS $6.95-$7.15.
- Acquired IPR&D $448M, including $389M for MiroBio; operating CF $2.9B in Q3.